Adam Crystal - Jul 1, 2021 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Medical Officer
Signature
/s/ Shoaib Ghias, Attorney-in-Fact
Stock symbol
CCCC
Transactions as of
Jul 1, 2021
Transactions value $
-$472,166
Form type
4
Date filed
7/6/2021, 08:00 PM
Next filing
Aug 2, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Options Exercise $97.5K +15K $6.50 15K Jul 1, 2021 Direct F1
transaction CCCC Common Stock Sale -$504K -13.3K -88.67% $37.93* 1.7K Jul 1, 2021 Direct F1, F2
transaction CCCC Common Stock Sale -$65.2K -1.7K -100% $38.38* 0 Jul 1, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CCCC Stock Option (Right to Buy) Options Exercise $0 -15K -9.54% $0.00 142K Jul 1, 2021 Common Stock 15K $6.50 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on January 21, 2021.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.33 to $38.25. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3 25% of this option vested and became exercisable on February 14, 2020, with the remainder vesting in 16 equal quarterly installments thereafter.